Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPASIL vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Reserpine (Serpasil) is an indole alkaloid that depletes catecholamines (norepinephrine, dopamine) and serotonin from central and peripheral nerve endings by irreversibly binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing storage of monoamines in presynaptic vesicles, leading to depletion and reduced sympathetic outflow.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Mild to moderate hypertension (adjunctive therapy),Psychotic disorders (off-label),Tardive dyskinesia (off-label),Huntington disease (off-label)
Hypertension
Hypertension: 0.1–0.25 mg orally once daily; initial dose 0.1 mg, maximum 0.5 mg/day. Psychosis (not first-line): 0.5–2 mg orally daily.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Terminal elimination half-life 45–168 hours (mean 100 h), reflecting prolonged adrenergic depletion; clinical effects persist beyond serum presence.
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Reserpine is extensively metabolized in the liver via hydrolysis and glucuronidation; specific CYP enzymes are not well characterized.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Primarily renal (approx. 60% unchanged and metabolites), biliary/fecal (approx. 40%), enterohepatic circulation negligible.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
~96% bound to plasma proteins (albumin and lipoproteins).
~90%, primarily to albumin
Vd 9.4 L/kg, indicating extensive tissue binding (particularly adrenergic neurons, brain, adipose).
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral: 30–40% due to extensive first-pass metabolism; IM/IV: 100%.
Oral: 50–60% (extensive first-pass metabolism)
No specific dose adjustment; use cautiously in severe renal impairment (Cr Cl <30 m L/min) due to risk of hypotension and CNS effects.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use due to risk of hepatic encephalopathy.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Hypertension: 0.02 mg/kg/day orally divided every 6–12 hours; maximum 0.25 mg/day. Psychosis: not recommended.
Not recommended for pediatric use; safety in children under 12 years not established.
Initiate at 0.05 mg orally once daily; increase slowly due to increased sensitivity and risk of hypotension, sedation, and depression.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
None
None
May cause severe depression with risk of suicide (discontinue if depression occurs),Use with caution in patients with history of peptic ulcer disease (increases gastric acid secretion),Use with caution in patients with renal impairment (may reduce renal blood flow),Avoid concomitant use with MAOIs (risk of hypertensive crisis),Electroshock therapy: discontinue reserpine 7-14 days prior,May cause biliary colic in patients with gallstones,May exacerbate arrhythmias in patients with cardiac disease
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Hypersensitivity to reserpine or any component,History of depression (especially suicidal),Active peptic ulcer disease,Ulcerative colitis,Electroconvulsive therapy (within 7-14 days),Concurrent MAO inhibitor therapy (or within 2 weeks of discontinuation),Pheochromocytoma
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid tyramine-rich foods (aged cheese, cured meats, fermented products, soy sauce, yeast extracts) as reserpine can potentiate pressor responses, leading to hypertensive crisis. Alcohol may increase sedative effects. Grapefruit juice may alter drug metabolism; limit intake.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
Reserpine (Serpasil) crosses the placenta. First trimester: no clear evidence of major malformations but risk of fetal bradycardia and hypothermia. Second and third trimesters: risk of neonatal bradycardia, hypotonia, lethargy, and respiratory depression. Use only if benefits outweigh risks.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Reserpine is excreted into breast milk. M/P ratio not established. Risk of infant bradycardia, GI upset, and nasal congestion. Not recommended during breastfeeding.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
No specific dose adjustment guidelines. Consider lower starting doses due to increased sensitivity. Monitor maternal blood pressure closely to avoid hypotension.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
Serpasil (reserpine) is an antihypertensive and antipsychotic that depletes catecholamines from peripheral sympathetic nerve endings and CNS. Onset is slow (3-6 days) and effects persist for weeks after discontinuation. Monitor for depression, especially in patients with history. Avoid in patients requiring MAOIs due to hypertensive crisis risk. Use with caution in peptic ulcer disease due to increased gastric acid secretion. Bradycardia and nasal congestion are common side effects.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take exactly as prescribed; do not stop suddenly as blood pressure may rise rapidly.,Report any symptoms of depression, mood changes, or suicidal thoughts immediately.,Avoid alcohol and over-the-counter cold or allergy medications containing decongestants.,May cause drowsiness or dizziness; avoid driving until you know how the drug affects you.,Contact your healthcare provider if you experience slow heartbeat, fainting, or severe stomach pain.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPASIL vs ALDORIL 15, answered by our medical review team.
SERPASIL is a Antihypertensive that works by Reserpine (Serpasil) is an indole alkaloid that depletes catecholamines (norepinephrine, dopamine) and serotonin from central and peripheral nerve endings by irreversibly binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing storage of monoamines in presynaptic vesicles, leading to depletion and reduced sympathetic outflow.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPASIL and ALDORIL 15 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPASIL is: Hypertension: 0.1–0.25 mg orally once daily; initial dose 0.1 mg, maximum 0.5 mg/day. Psychosis (not first-line): 0.5–2 mg orally daily.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPASIL and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPASIL is classified as Category C. Reserpine (Serpasil) crosses the placenta. First trimester: no clear evidence of major malformations but risk of fetal bradycardia and hypothermia. Second and third trimesters: ris. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.